14-day Premium Trial Subscription Sign Up For FreeGet Free

Cidara Therapeutics Stock Forecast NASDAQ:CDTX

Price Target and Analyst Ratings

Most Recent Rating

On September 22, 2021 "Aegis" gave "$9.00 - $8.00" rating for CDTX. The price target was set to $2.25+5.1%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-09-22 $9.00 - $8.00 Target Lowered by Aegis $2.24 $2.25+5.1%
2021-09-22 $6.25 Upgraded by WBB Securities $2.24 $2.14+2.4%
2021-03-10 Buy Initiated by Aegis $2.60 $9.00
2021-03-04 Buy Initiated by Aegis $2.34 $9.00
2021-03-04 Buy Initiated by Aegis $2.34
2020-11-06 Buy Reiterated by Maxim Group $2.32 $10.00
2020-08-26 Buy Target Lowered by Citigroup $3.41 $6.00 → $5.00
2020-08-13 Buy Reiterated by Oppenheimer $3.78 $6.00

CDTX Stock Trend

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled.

Given the current short-term trend, the stock is expected to rise 31.62% during the next 3 months and, with a 90% probability hold a price between $2.45 and $3.10 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-09-30 $1.87 $2.12 $2.37
2021-10-01 $1.88 $2.13 $2.38
2021-10-04 $1.88 $2.14 $2.39
2021-10-05 $1.89 $2.14 $2.39
2021-10-06 $1.90 $2.15 $2.40
2021-10-07 $1.91 $2.16 $2.41
2021-10-08 $1.92 $2.17 $2.42
2021-10-11 $1.93 $2.18 $2.43
2021-10-12 $1.94 $2.19 $2.44
2021-10-13 $1.95 $2.20 $2.45
2021-10-14 $1.96 $2.21 $2.46
2021-10-15 $1.97 $2.22 $2.47
2021-10-18 $1.97 $2.23 $2.48
2021-10-19 $1.98 $2.23 $2.48
2021-10-20 $1.99 $2.24 $2.49
2021-10-21 $2.00 $2.25 $2.50
2021-10-22 $2.01 $2.26 $2.51
2021-10-25 $2.02 $2.27 $2.52
2021-10-26 $2.03 $2.28 $2.53
2021-10-27 $2.04 $2.29 $2.54
2021-10-28 $2.05 $2.30 $2.55
2021-10-29 $2.06 $2.31 $2.56
2021-11-01 $2.06 $2.32 $2.57
2021-11-02 $2.07 $2.32 $2.57
2021-11-03 $2.08 $2.33 $2.58
2021-11-04 $2.09 $2.34 $2.59
2021-11-05 $2.10 $2.35 $2.60
2021-11-08 $2.11 $2.36 $2.61
2021-11-09 $2.12 $2.37 $2.62
2021-11-10 $2.13 $2.38 $2.63

About Cidara Therapeutics

Cidara Therapeutics Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation of CD101 for the treatment of recurrent vul... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT